Network pharmacology-based investigation and experimental validation of the mechanism of metformin in the treatment of acute myeloid leukemia

• Published in: European journal of medical research Vol. 29; no. 1; pp. 475 - 12
• Main Authors: Liu, Shaoyu, Xu, Mingming, Yang, Zhuofan, Li, Yangzi, Wu, Depei, Tang, Xiaowen
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 30.09.2024; BioMed Central; BMC
• Subjects: AML; Apoptosis; Apoptosis - drug effects; Cancer; Care and treatment; Cell Proliferation - drug effects; Diabetes therapy; Drug therapy; Gene Regulatory Networks - drug effects; Genes; Genomes; Genomics; HIF1A; Humans; Hypoxia-Inducible Factor 1, alpha Subunit - genetics; Hypoxia-Inducible Factor 1, alpha Subunit - metabolism; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - metabolism; Leukemia, Myeloid, Acute - pathology; Metformin; Metformin - pharmacology; Metformin - therapeutic use; Network pharmacology; Network Pharmacology - methods; Pharmacology; Protein Interaction Maps - drug effects; Protein-protein interactions; Proto-Oncogene Proteins c-akt - metabolism; Signal Transduction - drug effects; Type 2 diabetes; AML; Network pharmacology; Metformin; HIF1A; Apoptosis

Metformin, a widely used anti-diabetic agent, has shown significant anti-cancer properties as reported in in various cancers, including acute myeloid leukemia. However, the detailed mechanisms by which metformin influences acute myeloid leukemia remain unrevealed. Employing a synergistic approach of...